Healixa Inc. Completes Global AquaDuct Deposition Water Harvesting Technology Beta Development Program and Commences Pre-Commercialization Testing Program
Healixa Inc. Completes Global AquaDuct Deposition Water Harvesting Technology Beta Development Program and Commences Pre-Commercialization Testing Program
Field Trials to Begin Following Comprehensive Product and Independent Third-Party Water Quality Testing Program
全面產品和獨立第三方水質檢測計劃後將開始現場試驗
New York, NY, July 06, 2023 (GLOBE NEWSWIRE) -- Healixa, Inc. (OTC: EMOR) ("Healixa" or the "Company"), a technology company focusing on building and acquiring innovative and disruptive technologies in the clean water, health-tech, and green-tech industries, today announced that it has completed the beta development of its proprietary Global AquaDuct, Deposition Water Harvesting ("DWH) technology, significantly advancing its global commercialization plans.
紐約，紐約，2023年7月6日(環球通訊社)Healixa，Inc. (場外交易：Emor)(“Healixa”或“公司”)，一家專注於在清潔水、健康科技和綠色科技行業建立和收購創新和顛覆性技術的科技公司，今天宣佈已經完成了其專有技術的測試版開發環球高架橋，沉積水收集(“DWH”)技術，大大推進了其全球商業化計劃。
Global AquaDuct, Healixa's unique atmospheric water harvesting ("AWH") technology, can produce potable water directly from the earth's atmosphere by leveraging multiple advancements including its novel thermal deposition technology. Healixa's DWH technology directly addresses challenges that have previously stifled adoption of atmospheric water generation solutions, specifically delivering substantially improved operational performance including energy efficiency, no relative humidity dependency, and substantial reliable yields. To date, Healixa has already received over $75,000,000 in order indications for Global AquaDuct.
Healixa獨特的大氣集水(“AWH”)技術Global Aquaduct可以利用包括其新穎的熱沉積技術在內的多項先進技術，直接從地球大氣中生產飲用水。Healixa的DWH技術直接解決了以前阻礙採用大氣水發電解決方案的挑戰，特別是提供了大幅改善的運營性能，包括能源效率、不依賴相對濕度和相當可靠的產量。迄今為止，Healixa已經收到了超過$75,000,000按順序指示全球高架橋。
"I am pleased to announce the successful completion of our Global AquaDuct development program, our latest commercialization milestone. Thanks to the hard work and dedication of our team, we are able to enter the next phase of our strategic plan for Global AquaDuct which includes critical pre-production testing and confirmation of its water quality," said Ian Parker, Chairman and CEO of Healixa. "Based upon our rigorous internal development and testing regiments, we are confident in the performance and capabilities of our Global AquaDuct platform and are looking forward to the opportunity to deploy our initial pre-production units into the field."
Healixa董事長兼首席執行官Ian Parker表示：“我很高興地宣佈，我們的全球高架橋開發專案成功完成，這是我們最新的商業化里程碑。由於我們團隊的辛勤工作和奉獻精神，我們能夠進入全球高架橋戰略計劃的下一階段，其中包括關鍵的投產前測試和水質確認。”基於我們嚴格的內部開發和測試團隊，我們對我們的全球高架橋平臺的性能和能力充滿信心，並期待著有機會將我們最初的試生產單位部署到現場。“
The next phase of the Global AquaDuct commercialization plan involves rigorous final internal production testing and the critically important water quality evaluation conducted by an independent, third-party laboratory. Upon receipt of satisfactory water quality results, the Company anticipates quickly beginning building additional beta units for in-the-field beta testing of Global AquaDuct with potential customers and partners in early fall.
全球高架橋商業化計劃的下一階段包括由獨立的第三方實驗室進行嚴格的最終內部生產測試和至關重要的水質評估。在收到令人滿意的水質結果後，該公司預計將在初秋與潛在客戶和合作夥伴一起，迅速開始建造更多的Beta單元，用於全球高架橋的現場Beta測試。
About Healixa, Inc.
Healixa is a technology company focusing on building and acquiring innovative and disruptive technologies in the clean water generation, health-tech, and green-tech industries. Healixa embraces innovation by combining its intellectual properties, patents, strategic collaborations, and partnerships to create a "LaunchPad" of disruptive sustainable products. For more information, visit .
Healixa公司簡介
Healixa是一家技術公司，專注於在清潔水發電、健康技術和綠色技術行業建立和獲取創新和顛覆性技術。Healixa擁抱創新，將其知識產權、專利、戰略合作和合作夥伴關係結合在一起，創建了一個顛覆性可持續產品的“發射臺”。如需更多資訊，請訪問。
Safe Harbor Statement
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
安全港聲明
本新聞稿中包含的某些陳述可能構成前瞻性陳述。例如，在討論我們預期的研發計劃等時，會使用前瞻性陳述。這些前瞻性陳述僅基於對管理層的當前預期，受重大風險和不確定因素的影響，這些風險和不確定因素可能導致實際結果與前瞻性陳述中描述的大不相同，包括但不限於與合作夥伴關係和產品開發計劃的進度、時間、成本和結果有關的風險和不確定因素；在獲得監管批准或專利保護方面的困難或延遲；以及來自其他公司的競爭。除非法律另有要求，Healixa，Inc.沒有義務公開發布對這些前瞻性陳述的任何修訂，以反映本前瞻性陳述之後的事件或情況，或反映意外事件的發生。
Healixia Contact:
Bret Hedges
SVP of Strategic Partnerships
833-432-5492
Bret@healixa.com
和力霞聯繫方式：
Bret Hedge
戰略合作夥伴關係高級副總裁
833-432-5492
郵箱：bret@healixa.com
譯文內容由第三人軟體翻譯。